Transformed Sandoz Is Important Part Of Novartis
Executive Summary
A Sandoz generics division that is focusing more on biosimilars and hard-to-make small molecules remains “an important part of Novartis”, the Swiss group’s chief executive officer, Vas Narasimhan, told investors during a J.P. Morgan Healthcare Conference.
You may also be interested in...
Sandoz Head Francis To Leave Amid Move Towards Autonomy
Sandoz’ drive to greater efficiency and stronger profit margins through a group-wide transformation process has prompted the division’s global head, Richard Francis, to step down.
Sandoz Head Francis To Leave Amid Move Towards Autonomy
Sandoz’ drive to greater efficiency and stronger profit margins through a group-wide transformation process has prompted the division’s global head, Richard Francis, to step down.
Beximco Expands In US With Eight ANDAs From Sandoz
Beximco has bolstered its position in the US by bumping up its portfolio to 14 approved generics through a deal with Sandoz for a portfolio of eight ANDAs.